Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.

Cancer immunology research - 1 Dec 2014

Kibe Shiro, Yutani Shigeru, Motoyama Satoru, Nomura Takanobu, Tanaka Natsuki, Kawahara Akihiko, Yamaguchi Tomohiko, Matsueda Satoko, Komatsu Nobukazu, Miura Masatomo, Hinai Yudai, Hattori Satoshi, Yamada Akira, Kage Masayoshi, Itoh Kyogo, Akagi Yoshito, Sasada Tetsuro

Abstract excerpt

The prognosis of advanced colorectal cancer (aCRC) remains poor, and development of new therapeutic approaches, including immunotherapy, is needed urgently. Herein we report on our phase II study of personalized peptide vaccination (PPV) in 60 previously treated patients with aCRC, who had failed at least one regimen of standard chemotherapy and/or targeted therapy. For PPV, a maximum of four HLA-matched peptides...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to C-Reactive Protein
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Antigens

Share to Immunization, Secondary

Share to Receptors, Interleukin-6

Share to Retreatment

Share to T-Lymphocytes, Cytotoxic

Share to Vaccines, Subunit

Source

Identifiers

PMID: 25351849
DOI: 10.1158/2326-6066.CIR-14-0035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.PMID 25351849Read ↗

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.Semantic proximity Read ↗

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responsesSemantic proximity Read ↗

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapySemantic proximity Read ↗

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicitySemantic proximity Read ↗

Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.Semantic proximity Read ↗

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.Semantic proximity Read ↗

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccinesSemantic proximity Read ↗

New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.Semantic proximity Read ↗

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccinesSemantic proximity Read ↗

Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.Semantic proximity Read ↗

Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T CellsSemantic proximity Read ↗

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.